top of page
Search Results
Results found for "IBD"
- 📰 GPCR Weekly News, March 18 to 24, 2024
Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease (IBD
- Mechanism vs. Assumption: A Model-First Path to Getting GPCR MoA Right
Recursion completes Exscientia acquisition, signaling a fresh AI–GPCR chapter; OMass–Genentech deal in IBD
- Unlock the Future of GPCR Science: Breakthroughs and Courses Await | Sep 2 - Sep 8, 2024
Oncology and Immunology A disturbed metabolite-GPCR axis is associated with microbial dysbiosis in IBD
bottom of page